Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis. The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combinati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sekeres, Mikkael A., Tiu, Ramon V., Komrokji, Rami, Lancet, Jeffrey, Advani, Anjali S., Afable, Manuel, Englehaupt, Ricki, Juersivich, Joyce, Cuthbertson, David, Paleveda, Jennifer, Tabarroki, Ali, Visconte, Valeria, Makishima, Hideki, Jerez, Andres, Paquette, Ronald, List, Alan F., Maciejewski, Jaroslaw P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525020/
https://ncbi.nlm.nih.gov/pubmed/22915641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-434639
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados